Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

NCT03489343 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Cancer
Solid Tumor
Lymphoma

Interventions

DRUG: Sym023

Sponsor

Symphogen A/S